Regional Head responsible for leading a team of 40 people to drive excellence in Value Access & Medical Affairs strategy, planning and execution to support the registration, reimbursement, and appropriate use of medicines. This entails driving key initiatives that enable World Class Evidence Generation, Scientific Communication & Exchange to effectively demonstrate the value of medicines to Physicians, Payers/Purchasers, Policy makers & PatientsValue Access▪ Leadership in coordination of customer insights, assessments, development of integrated EvGen strategies & timely execution of programmes ▪ Supported teams in P&R dossiers, HE models, submissions & negotiations with relevant Authorities, HTA bodies, Sci Societies & Institutions▪ Led Regional Workshops to raise awareness of emerging payer / HTA regulations, clinical care pathways, access evidence implications & capability requirements ▪ Established a Regional EvGen Committee to drive efficiency, expedite decision-making, & ensure alignment/oversight on strategic study investments ▪ Established a Regional EvGen Study Ops team to efficiently manage the execution & delivery of key studies with budget of approx. £3m▪ Led the design & roll out of an innovative Regional EvGen capability building Academy ▪ Represent GSK at relevant international scientific & industry associations/bodiesMedical Excellence▪ Accountable for the strategic planning & delivery framework for an industry leading Omnichannel system▪ Collaboration with Medical TA Leads in the development of digital content & content platform ▪ Ensured the development of a SRM model to drive the optimal deployment of Medical/EvGen leaders ▪ Established a unique people development programme providing accelerated on-the-job learning ▪ Embedded a performance culture through timely development, implementation & review of KPIs / dashboards & surveys ▪ Budget management (> 80 staff), project budgets & oversight of country resourcing/ budgeting

Lead a project team in the design, development and delivery of a Global Capability Programme for Value Access

• Lead the implementation and embedding of the MENA-CIS medical organisations new ways of working in line with the new business model • Lead the MENA-CIS Value Access organisation to drive excellence in the planning & execution of Value Access strategies to support reimbursement and market access; and the appropriate utilisation of medicines

MEA lead responsible for building an area capability and to drive excellence in integrated Evidence Generation and Access planning and execution to support effective registration, reimbursement and access, long-term safety /effectiveness assessment of GSK medicines- Health Economics / Health Outcomes- Epidemiology- Pricing- Reimbursement & Access- New Product Introduction

MEA Area lead for Epidemiology and Health Outcomes strategies and projects to support access to medicines/vaccines.

Access to Medicines CoE & Oncology CoE- EU Market Access lead, Oncology assets• Develop and implement appropriate pricing, reimbursement and market access strategies for oncology assets and indications

Global Health Outcomes• Global strategic lead, Immuno-Inflammation assets: Lead the planning, development, and implementation of reimbursement and market access strategies across the portfolio to support the objectives of programmes and assets during development and launch

• OR lead, responsible for Lipitor and other Cardiovascular Therapies: Lead the planning, development and implementation of Health Economic and Outcomes Research (HEOR) strategies  Ensure that related HEOR studies (economic models, clinical and administrative database studies) were optimally designed / administered to deliver meaningful outcomes data to support messages for stakeholders Develop and implement submissions for National Bodies that provide guidance on the promotion of good health and the prevention and treatment of ill health i.e. NICE (England & Wales), SMC (Scotland) and AWMSG (Wales) Develop market access toolkits for regional specialist fieldforce representatives  Train specialist fieldforce representatives on the use of HEOR data / tools

• Global support across the Respiratory Therapy Area, specifically: Design and conduct health economic and outcome studies to demonstrate the clinical, humanistic and economic benefits of assets in a rigorous and timely manner Ensure optimal and accepted research methodologies are used to demonstrate the benefits of GSK assets Analyse and interpret studies to provide customers with relevant economic data Draft analysis plans for administrative claims and database studies, and perform analyses using SAS as needed

• Collation / analysis of data on financial and economic aspects of mental health in London• Review data on established cost-effectiveness of mental health service interventions• Draft report on economic aspects and financing policy of London’s mental health services